Proffitt & Goodson’s Repligen RGEN Stock Holding History

Proffitt & Goodson’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10	Closed	-$1.34K	–	412
2025 Q3	$1.34K	Buy	+10	New	+$1.22K	﹤0.01%	373

Other funds holding RGEN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Proffitt & Goodson's RGEN Position: Q4 2025 in Review

Proffitt & Goodson sold out of Repligen (RGEN) in Q4 2025, closing a stake of 10 shares — an estimated $1.34K sold.

Proffitt & Goodson first reported a position in RGEN in Q3 2025 and held it in 1 quarter. The position peaked at $1.34K in Q3 2025. 474 funds tracked by Wall St. Rank hold RGEN as of Q4 2025.

Proffitt & Goodson reported no remaining Repligen position as of Q4 2025 after selling out during the quarter.
Proffitt & Goodson sold 10 Repligen shares in Q4 2025, an estimated $1.34K.
Proffitt & Goodson first reported a position in Repligen in Q3 2025 and held it in 1 quarter.
Proffitt & Goodson's Repligen position peaked at $1.34K in Q3 2025.
474 funds tracked by Wall St. Rank held Repligen as of Q4 2025.

Based on Proffitt & Goodson's 13F filing for Q4 2025, filed 27 Jan 2026.